Edgewise to advance heart drug into Phase 3 following mid-stage data update

Edgewise plans to start a Phase 3 trial for HCM drug EDG-7500 in Q4, citing 12-week Phase 2 data showing NT-proBNP response rates above 74% across patient subtypes. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act…

Ayisha Sharma · 2026-06-16

Edgewise Therapeutics has shared plans to advance its drug candidate for a genetic heart disease into a registrational study on the back of updated Phase 2 data. The biotech said Tuesday ...

Source: Endpoints News